The results presented here demonstrate that RHOB expression is predictive of EGFR‐TKI response and suggest that an EGFR‐TKI–AKT inhibitor combination may provide a clinical advantage to prevent resistance to EGFR‐TKI in RHOB‐positive tumor patients. Here, AKT1 is linked to neoplasm.